Versor Investments LP Cuts Stock Position in Privia Health Group, Inc. $PRVA

Key Points

• Versor Investments LP significantly reduced its stake in Privia Health Group, Inc. by 74.3%, owning only 9,500 shares after selling 27,400 shares.
• Privia Health Group reported earnings of $0.02 per share, missing estimates and experiencing a 23.4% revenue increase year-over-year with revenues of $521.15 million.
• Analysts have varying opinions on the stock, with price targets ranging from $28.00 to $36.00, suggesting a generally optimistic outlook for PRVA.

Versor Investments LP reduced its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 74.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,500 shares of the company's stock after selling 27,400 shares during the quarter. Versor Investments LP's holdings in Privia Health Group were worth $213,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. US Bancorp DE increased its position in shares of Privia Health Group by 2.4% during the 1st quarter. US Bancorp DE now owns 18,487 shares of the company's stock valued at $415,000 after purchasing an additional 429 shares during the last quarter. Park Avenue Securities LLC increased its position in Privia Health Group by 3.6% during the first quarter. Park Avenue Securities LLC now owns 15,229 shares of the company's stock valued at $342,000 after acquiring an additional 532 shares during the last quarter. CWM LLC raised its stake in shares of Privia Health Group by 50.3% in the first quarter. CWM LLC now owns 1,804 shares of the company's stock valued at $40,000 after acquiring an additional 604 shares during the period. Financial Management Professionals Inc. lifted its holdings in shares of Privia Health Group by 28.7% in the 1st quarter. Financial Management Professionals Inc. now owns 3,383 shares of the company's stock worth $76,000 after acquiring an additional 754 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Privia Health Group by 113.1% in the 1st quarter. GAMMA Investing LLC now owns 2,866 shares of the company's stock worth $64,000 after acquiring an additional 1,521 shares during the last quarter. 94.48% of the stock is owned by institutional investors.

Privia Health Group Price Performance

Shares of NASDAQ:PRVA traded down $0.09 during trading hours on Thursday, hitting $21.66. The company's stock had a trading volume of 113,534 shares, compared to its average volume of 833,465. The firm's fifty day moving average price is $20.89 and its 200 day moving average price is $22.68. Privia Health Group, Inc. has a 52 week low of $16.47 and a 52 week high of $26.09. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of 196.79, a P/E/G ratio of 3.10 and a beta of 0.80.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.03). The business had revenue of $521.15 million for the quarter, compared to analysts' expectations of $466.97 million. Privia Health Group had a net margin of 0.78% and a return on equity of 2.13%. The business's quarterly revenue was up 23.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 earnings per share. Privia Health Group has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on PRVA shares. Zacks Research upgraded shares of Privia Health Group from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Piper Sandler reduced their price target on Privia Health Group from $36.00 to $35.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Evercore ISI decreased their price target on Privia Health Group from $30.00 to $28.00 and set an "outperform" rating for the company in a research note on Wednesday, July 9th. Barclays upped their price objective on Privia Health Group from $23.00 to $24.00 and gave the company an "equal weight" rating in a research report on Tuesday, May 27th. Finally, JPMorgan Chase & Co. lifted their target price on Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.00.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.